Biotech spinout from the University of Oxford developing first-in-class targeted protein degradation therapies for acute leukaemias, led by lead candidate DBT 3757 targeting MLLT1/3.
Industries
Frequently Asked Questions
Where is Dark Blue Therapeutics located?
Dark Blue Therapeutics is located in Oxford, United Kingdom.
What industries does Dark Blue Therapeutics operate in?
Dark Blue Therapeutics operates in the following industries: biotechnology, oncology, pharmaceuticals.
What is the primary focus of Dark Blue Therapeutics?
The company is a biotechnology firm dedicated to discovering and developing precision medicines for the treatment of genetically defined cancers.
Where is Dark Blue Therapeutics headquartered?
The organization is based in Oxford, United Kingdom, situated within a major global hub for life sciences and medical innovation.
What scientific approach does Dark Blue Therapeutics take towards oncology?
They utilize a precision oncology platform focused on identifying and targeting specific molecular vulnerabilities in tumor cells, including those involved in the DNA damage response.
What is the ultimate goal of Dark Blue Therapeutics?
The mission of the company is to transform the treatment landscape for cancer patients by providing effective, targeted therapies for conditions that currently have limited treatment options.
Does Dark Blue Therapeutics focus on specific types of cancer?
While their platform is broadly applicable to precision oncology, they specifically target cancers with well-defined genetic drivers where targeted inhibition can lead to significant clinical benefits.